HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RIBOLIFE-B

53.600

-2.850-5.05%

Volume:432.20K

Turnover:23.45M

Market Cap:9.11B

PE:-25.52

High:56.450

Open:56.050

Low:53.300

Close:56.450

52wk High:95.800

52wk Low:43.600

Shares:170.00M

HK Float Shares:170.00M

Volume Ratio:1.12

T/O Rate:0.25%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.100

ROE:-17.59%

ROA:-3.85%

PB:4.51

PE(LYR):-25.52

PS:16.79

Loading ...

Overview Company News Filings

Suzhou Ribo submits EMA phase 2b trial application for Vortosiran in SPAF

RIBOLIFE-B Maintains Stable Share Capital in March; 2.11 Million Pre-IPO Options Remain Unexercised

Bulletin Express

China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026

Shrinking Losses At Suzhou Ribo Life Science (SEHK:6938) Test Bearish Profitability Narratives

Simply Wall St.

RIBOLIFE-B (06938) Proposes Adoption of H Share Option Scheme and H Share Incentive Plan

RIBOLIFE-B Reports 2025 Revenue of Approximately 1.485 Billion Yuan, Up 4.1% Year-on-Year

RIBOLIFE-B Appoints Anders Gabrielsen as Chief Medical Officer

Ribo Life Science Names New Chief Medical and Business Officers, Effective 25 March 2026

Bulletin Express

Suzhou Ribo Life Science Co Ltd - FY Revenue RMB148.5 Mln

THOMSON REUTERS

Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million

Suzhou Ribo Life Science Attends RNA Leaders Europe Conference in Vienna

Suzhou Ribo Life Science to present ex-hepatic siRNA delivery data at RNA Leaders Europe Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/06938/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":53.6,"timestamp":1789104756936,"preClose":56.45,"halted":0,"volume":432200,"delay":0,"changeRate":-0.050487156775907906,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"Trading","change":-2.85,"latestTime":"09-11 13:33:51","open":56.05,"high":56.45,"low":53.3,"amount":23451110,"amplitude":0.055802,"askPrice":53.65,"askSize":3200,"bidPrice":53.5,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-1.149,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789114200000},"marketStatusCode":2,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":56.45,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":1.117734,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170000000,"roa":"-3.85%","roe":"-17.59%","lyrEps":-2.100221,"volumeRatio":1.117734,"shares":170000000,"dividePrice":0,"high":56.45,"amplitude":0.055802,"preClose":56.45,"low":53.3,"week52Low":43.6,"pbRate":"4.51","psRate":"16.79","week52High":95.8,"institutionHeld":0,"latestPrice":53.6,"committee":-0.777778,"eps":-2.100221,"divideRate":0,"volume":432200,"delay":0,"ttmEps":-1.149,"open":56.05,"prevYearClose":57.97,"prevWeekClose":66.05,"prevMonthClose":60.25,"prevQuarterClose":46.9,"fiveDayClose":66.05,"twentyDayClose":52.9,"sixtyDayClose":50},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"06938","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787794200000,"name":null,"time":"","dateTimestamp":1787760000000,"actualEps":null},{"market":"HK","date":"2026-03-25","symbol":"06938","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774368000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1784304000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-09-10","current":-46.64926,"percent":0.093525,"low":-56.914635,"twenty":-39.573842,"median":-31.276437,"eighty":-26.666946,"high":-23.913403,"avg":-33.673975,"sd":8.083787,"marketCap":9627824669},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-27","current":-30.985978,"twenty":-48.084787,"median":-40.112534,"eighty":-38.372934,"marketCap":9755740852},{"date":"2026-04-02","current":-34.881193,"twenty":-47.185618,"median":-39.757485,"eighty":-36.526858,"marketCap":11034902677},{"date":"2026-04-10","current":-37.770699,"twenty":-46.28708,"median":-39.613953,"eighty":-36.479378,"marketCap":12041176646},{"date":"2026-04-17","current":-35.241421,"twenty":-45.408639,"median":-38.832211,"eighty":-35.918978,"marketCap":11239568569},{"date":"2026-04-24","current":-33.421304,"twenty":-43.677981,"median":-38.300657,"eighty":-35.241421,"marketCap":10659681875},{"date":"2026-04-30","current":-32.557368,"twenty":-42.07346,"median":-37.836456,"eighty":-34.614071,"marketCap":10386794019},{"date":"2026-05-08","current":-32.498031,"twenty":-41.169053,"median":-37.354591,"eighty":-33.058756,"marketCap":10403849510},{"date":"2026-05-15","current":-32.120533,"twenty":-40.738524,"median":-36.586666,"eighty":-32.493391,"marketCap":10310044309},{"date":"2026-05-22","current":-30.090442,"twenty":-40.591323,"median":-35.918978,"eighty":-32.095834,"marketCap":9636352415},{"date":"2026-05-29","current":-30.88841,"twenty":-40.296947,"median":-35.448939,"eighty":-31.691849,"marketCap":9926295762},{"date":"2026-06-05","current":-28.193848,"twenty":-40.051892,"median":-35.061307,"eighty":-30.899503,"marketCap":9073521212},{"date":"2026-06-12","current":-27.046231,"twenty":-39.859077,"median":-34.61525,"eighty":-30.390832,"marketCap":8698300410},{"date":"2026-06-18","current":-26.187923,"twenty":-39.726813,"median":-33.720381,"eighty":-29.853022,"marketCap":8442468045},{"date":"2026-06-26","current":-23.913403,"twenty":-39.627323,"median":-32.945231,"eighty":-29.564677,"marketCap":7671559851},{"date":"2026-07-03","current":-27.120201,"twenty":-39.476172,"median":-32.527699,"eighty":-28.324896,"marketCap":8706828155},{"date":"2026-07-10","current":-25.658884,"twenty":-39.120404,"median":-32.474833,"eighty":-27.529192,"marketCap":8227568858},{"date":"2026-07-17","current":-25.917703,"twenty":-38.802803,"median":-32.09845,"eighty":-26.657872,"marketCap":8340135099},{"date":"2026-07-24","current":-28.402389,"twenty":-38.680546,"median":-32.07594,"eighty":-26.891702,"marketCap":9141743176},{"date":"2026-07-31","current":-24.94248,"twenty":-38.662044,"median":-31.566896,"eighty":-26.553964,"marketCap":8043369555},{"date":"2026-08-07","current":-27.580979,"twenty":-37.939269,"median":-30.913769,"eighty":-26.515913,"marketCap":8911494047},{"date":"2026-08-14","current":-27.888785,"twenty":-37.902214,"median":-30.842167,"eighty":-26.553964,"marketCap":9022354739},{"date":"2026-08-21","current":-28.090305,"twenty":-37.770699,"median":-30.35874,"eighty":-26.553964,"marketCap":9107632194},{"date":"2026-08-28","current":-53.27383,"twenty":-37.770699,"median":-30.842167,"eighty":-26.562391,"marketCap":10540293438},{"date":"2026-09-04","current":-56.914635,"twenty":-38.685171,"median":-30.913769,"eighty":-26.600296,"marketCap":11265151805},{"date":"2026-09-10","current":-48.576855,"twenty":-39.573842,"median":-31.276437,"eighty":-26.666946,"marketCap":9627824669}],"updateTime":1789104831107},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627252464","title":"Suzhou Ribo submits EMA phase 2b trial application for Vortosiran in SPAF","url":"https://stock-news.laohu8.com/highlight/detail?id=2627252464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627252464?lang=en_us&edition=fundamental","pubTime":"2026-04-14 08:00","pubTimestamp":1776124845,"startTime":"0","endTime":"0","summary":"Suzhou Ribo submitted Phase 2b clinical trial application to European Medicines Agency for Vortosiran in stroke prevention in atrial fibrillation.Vortosiran  targets factor XI via siRNA, aiming to reduce thromboembolic risk with lower bleeding risk than current anticoagulants.Company said Vortosiran Phase 2a trial in coronary artery disease in Europe has been completed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 14, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL6dkqmC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157500309","title":"RIBOLIFE-B Maintains Stable Share Capital in March; 2.11 Million Pre-IPO Options Remain Unexercised","url":"https://stock-news.laohu8.com/highlight/detail?id=1157500309","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157500309?lang=en_us&edition=fundamental","pubTime":"2026-04-09 17:05","pubTimestamp":1775725511,"startTime":"0","endTime":"0","summary":"For the month ended 31 March 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) reported no changes in its authorised, registered or issued share capital. Authorised and issued ordinary H-shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172541363","title":"China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1172541363","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172541363?lang=en_us&edition=fundamental","pubTime":"2026-04-03 10:54","pubTimestamp":1775184869,"startTime":"0","endTime":"0","summary":"According to statistics from the NMPA and PharmaGO, the total business development value for domestic innovative drugs in the first quarter of 2026 exceeded $60 billion, surpassing the full-year 2024...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023057109.AUD","IE00B5MMRT66.SGD","BK1161","159992","LU0588546209.SGD","LU2778985437.USD","BK1583","LU0348735423.USD","LU0417516902.SGD","LU0348766576.USD","LU0348784397.USD","LU1303224171.USD","LU1794554557.SGD","LU1969619763.USD","LU0348827113.USD","LU2476274308.USD","LU0561508036.HKD","LU0359201885.HKD","LU0307460666.USD","LU0417516738.SGD","09926","LU2328871848.SGD","06978","06938","BK1574","LU0359202008.SGD","LU0348825331.USD","BK1500","LU1719994722.HKD","LU0348783233.USD","LU1251922891.USD","09995","LU2399975544.HKD","LU0634319403.HKD","LU1720050803.USD","LU1770034418.SGD","BK1191","LU0348767384.USD","BK1588","LU0540923850.HKD","06160","01877","LU1961090484.USD","LU2543165471.USD","IE00BPRC5H50.USD","LU0359201612.USD","LU2476274720.SGD","01276","LU0417516571.SGD","BK1515","LU2488822045.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622868063","title":"Shrinking Losses At Suzhou Ribo Life Science (SEHK:6938) Test Bearish Profitability Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2622868063","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622868063?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:19","pubTimestamp":1774523958,"startTime":"0","endTime":"0","summary":"Setting the Scene: Suzhou Ribo Life Science's Latest Numbers\nSuzhou Ribo Life Science (SEHK:6938) has posted another loss for FY 2025, with first half revenue of ¥103.8 million and a basic EPS loss of ¥0.68, while trailing twelve month revenue sits at ¥148.5 million against a TTM EPS loss of ¥2.11. Looking back, revenue has moved from ¥66.3 million in 1H 2024 to ¥76.3 million in 2H 2024 and then to ¥103.8 million in 1H 2025, while basic EPS losses over these halves have gone from ¥1.07 to...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/shrinking-losses-at-suzhou-ribo-life-science-sehk6938-test-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/shrinking-losses-at-suzhou-ribo-life-science-sehk6938-test-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199028891","title":"RIBOLIFE-B (06938) Proposes Adoption of H Share Option Scheme and H Share Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1199028891","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199028891?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:55","pubTimestamp":1774450531,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that on March 25, 2026, the board of directors resolved to propose the adoption of the company's H Share Option Scheme and H Share Incentive Plan (collectively referred...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130407819","title":"RIBOLIFE-B Reports 2025 Revenue of Approximately 1.485 Billion Yuan, Up 4.1% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1130407819","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130407819?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:43","pubTimestamp":1774449788,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced its 2025 financial results, achieving revenue of approximately 1.485 billion yuan, representing a 4.1% increase compared to the previous year. Gross profit reached about...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164454835","title":"RIBOLIFE-B Appoints Anders Gabrielsen as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=1164454835","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164454835?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:42","pubTimestamp":1774449767,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced the appointment of Dr. Anders Gabrielsen as Chief Medical Officer. Dr. Gabrielsen will oversee the company's overall clinical development, medical affairs, and regulatory...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147245685","title":"Ribo Life Science Names New Chief Medical and Business Officers, Effective 25 March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1147245685","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147245685?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:41","pubTimestamp":1774449667,"startTime":"0","endTime":"0","summary":"On 25 March 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced senior management changes aimed at strengthening its global clinical and commercial operations. Dr. Anders...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622072652","title":"Suzhou Ribo Life Science Co Ltd -  FY Revenue RMB148.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072652","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072652?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:30","pubTimestamp":1774449009,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D0XQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622725680","title":"Suzhou Ribo Life Science FY2025 administrative expenses jump 28% to RMB118 million; revenue rises 4.1% to RMB149 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622725680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622725680?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:29","pubTimestamp":1774448990,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science posted FY2025 loss before tax that widened 10.7% to RMB285 million.FY2025 administrative expenses jumped 28% to RMB118 million on higher listing expenses and increased professional and consulting service fees.FY2025 loss per share widened to RMB2.11 from RMB2.10.FY2025 revenue rose 4.1% to RMB149 million on higher collaboration revenue from the Boehringer Ingelheim agreement and higher sales of nucleoside monomers-related products.FY2025 gross profit climbed 3.3% to RMB135 million, while gross profit margin fell 0.8 percentage points to 90.9%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Infor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLFDTsT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620381687","title":"Suzhou Ribo Life Science Attends RNA Leaders Europe Conference in Vienna","url":"https://stock-news.laohu8.com/highlight/detail?id=2620381687","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620381687?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:33","pubTimestamp":1774006383,"startTime":"0","endTime":"0","summary":"Ribo attended the RNA Leaders Europe conference in Vienna, where it delivered a presentation.The company discussed its RiboPepSTAR platform for targeted delivery of siRNA therapies to organs outside the liver.Ribo said preclinical studies showed up to 80% target gene expression reduction in kidney proximal tubular cells.Ribo reported a 96% gene expression reduction in adipose tissue in non-human primates.Ribo said RiboGalSTAR has supported seven clinical programs and partnerships valued at more than USD 6 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via PR Newswire  on March 20, 2026, and is solely responsible for the informatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL7X0SXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620144844","title":"Suzhou Ribo Life Science to present ex-hepatic siRNA delivery data at RNA Leaders Europe Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620144844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620144844?lang=en_us&edition=fundamental","pubTime":"2026-03-17 11:00","pubTimestamp":1773716414,"startTime":"0","endTime":"0","summary":"Ribo is scheduled to speak at the RNA Leaders Europe Conference in Vienna, Austria on March 19, 2026. Event materials are available at .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9GWGgm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":92,"code":"91000000","status":"200"}]}}